Issued by: CENS
Issued on: 2009/03/20
By: Quincy Liang

Taipei, March 20, 2009 (CENS)--Scandinavian Health Ltd. (SHL) Group, the world`s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices with production facilities in Taiwan, recently announced that its newly developed precision pen injector (PPI) won the 2009 red dot product design award.

As one of the world`s most important design competition systems, red dot is a worldwide symbol of design and quality, with only 10% of all entries receiving an award, providing a good indicator of the commercial potential of a product. The PPI emerged a winner among 3,200 entries from 49 countries and will be displayed in the red dot museum.

Jochen Ratjen, SHL`s chief industrial designer for the PPI project, said: "As a company, we have been excited about the mechanical and aesthetical design of this product. We were confident that this would be recognized at some stage and are delighted it came so early and from such a prestigious design competition."

According to SHL, the PPI is designed to deliver small but highly accurate doses of Restylane Vital Light, a treatment for rejuvenating delicate skin, produced by Swedish biomedical firm Q-Med AB. The innovative device was praised by doctors and clinicians during the recent launch at IMCAS (International Master Course on Aging Skin) 2009 annual meeting in Paris for its ease-of-use and compact design.

Commenting on what this means for the company, Steven Kaufman, SHL`s marketing director said: "Winning a red dot award is an honor for everyone here at SHL and is representative of SHL`s commitment to innovation."

Original Article

About SHL

SHL is the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices. We have over 1,500 staff globally (1000 staff in Taiwan), with our primary design centers located in the USA and Sweden and manufacturing centers located in Asia.

SHL supplies auto injectors, pen injectors and inhaler systems to global pharmaceutical and biotech companies. Significant investment in R&D has enhanced our broad pipeline of “next generation” drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.

Our organization consists of three distinct group companies:

SHL Medical
Designs, develops and manufactures advanced drug delivery devices for leading pharmaceutical and biotech companies

SHL Healthcare
Develops and manufactures equipment solutions for home, hospital and long term care use

SHL Technologies
Provides contract manufacturing and engineering services for the production of complex medtech and industrial products

For additional information visit www.shl-group.com or contact us at 這個 E-mail 地址已經被防止灌水惡意程式保護，您需要啟用 Java Script 才能觀看